Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Wednesday, June 12, 2024
Prior results of IMpower010, which demonstrated significant improvement in disease-free survival with atezolizumab vs best supportive care, led to the worldwide approval of atezolizumab in PD-L1–positive, stage II to IIIA non–small cell lung cancer (NSCLC). During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract LBA8035), Heather A. Wakelee, MD, of Stanford University Medical Center, California, and colleagues presented results from the final disease-free survival and second overall survival analysis of IMpower010, which support the use of adjuvant atezolizumab in this patient population.
“These results provide the first cancer immunotherapy data with at least 5 years of follow-up from a phase III study in resectable NSCLC,” the investigators concluded. “...Disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in the PD-L1[–positive] stage II to IIIA populations.”
The IMpower010 study enrolled more than 1,200 patients with stage IB to IIIA, resected NSCLC; the study design was previously described (ClinicalTrials.gov identifier NCT02486718). Disease-free survival was assessed in patients with at least 1% of tumor cells expressing PD-L1, followed by all patients with stage II to IIIA NSCLC, then in the intent-to-treat (stage IB–IIIA) population. Overall survival was evaluated in the intent-to-treat population. Disease-free survival was measured at 3 and 5 years, as well as in patients with at least 50% PD-L1–positive tumor cells and stage II to IIIA NSCLC.
At data cutoff, the minimum follow-up was 60 months. Disease-free survival and overall survival were improved among patients with at least 1% and 50% PD-L1–positive tumor cells who were treated with atezolizumab vs chemotherapy. In the 1% and higher PD-L1–positive NSCLC tumor cell population, the disease-free survival was nearly doubled among patients given atezolizumab vs chemotherapy (68.5 vs 37.3 months). The survival data and safety profile of atezolizumab were consistent with prior findings.
For more information, see a video with Dr. Wakelee on JNCCN 360.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
